We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+15.25%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$133M
AUM Growth
+$5.69M
Cap. Flow
+$3.69M
Cap. Flow %
2.77%
Top 10 Hldgs %
72.54%
Holding
56
New
1
Increased
8
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$1.79M
2
STOK icon
Stoke Therapeutics
STOK
+$745K
3
IMGN
Immunogen Inc
IMGN
+$472K
4
AXGN icon
Axogen
AXGN
+$373K
5
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$365K

Top Sells

Rank Stock Value
1
HROW icon
Harrow
HROW
+$660K
2
IFRX icon
InflaRx
IFRX
+$89.5K
3
NKTR icon
Nektar Therapeutics
NKTR
+$64K
4
ELTX icon
Elicio Therapeutics
ELTX
+$32K
5
AWH
Aspira Women's Health Inc. Common Stock
AWH
+$22K

Sector Composition

Rank Sector Weight
1 Healthcare 96.02%
2 Energy 3.95%
3 Consumer Staples 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$46.6M 34.92%
728,585
– –
PRTA icon
2
Prothena Corp
PRTA
$453M
$10.7M 7.99%
156,111
+27,716
+22% +$1.79M
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$7.94M 5.95%
84,240
– –
BDSX icon
4
Biodesix
BDSX
$209M
$6.2M 4.65%
251,982
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.38B
$5.97M 4.48%
249,400
– –
QDEL icon
6
QuidelOrtho
QDEL
$1.19B
$5.4M 4.05%
65,203
+3,897
+6% +$341K
ELUT icon
7
Elutia
ELUT
$42M
$3.91M 2.93%
1,655,184
– –
IMGN
8
DELISTED
Immunogen Inc
IMGN
$3.59M 2.69%
190,000
+40,000
+27% +$472K
UTHR icon
9
United Therapeutics
UTHR
$22.7B
$3.31M 2.48%
15,000
– –
OVV icon
10
Ovintiv
OVV
$16.2B
$3.21M 2.4%
84,200
– –
HROW icon
11
Harrow
HROW
$1.74B
$2.86M 2.14%
150,000
-30,000
-17% -$660K
PHR icon
12
Phreesia
PHR
$662M
$2.56M 1.92%
82,700
– –
MASI
13
DELISTED
Masimo
MASI
$2.51M 1.88%
15,280
– –
FHTX icon
14
Foghorn Therapeutics
FHTX
$305M
$1.86M 1.4%
264,843
– –
INBX
15
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.83M 1.37%
70,448
– –
AXDX
16
DELISTED
Accelerate Diagnostics
AXDX
$1.82M 1.37%
225,239
– –
ALKS icon
17
Alkermes
ALKS
$8.79B
$1.56M 1.17%
50,000
– –
ATEC icon
18
Alphatec Holdings
ATEC
$1.31B
$1.44M 1.08%
80,000
– –
ETRN
19
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$1.27M 0.95%
133,050
– –
CORT icon
20
Corcept Therapeutics
CORT
$9.72B
$1.11M 0.83%
50,000
– –
APLS
21
DELISTED
Apellis Pharmaceuticals
APLS
$1.09M 0.82%
12,000
– –
SLNO
22
DELISTED
Soleno Therapeutics
SLNO
$1.05M 0.79%
245,127
– –
PTGX icon
23
Protagonist Therapeutics
PTGX
$9.06B
$1.05M 0.79%
38,000
– –
DCGO icon
24
DocGo
DCGO
$64.3M
$1.03M 0.77%
110,000
– –
ISEE
25
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$984K 0.74%
25,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Birchview Capital held 56 positions worth $133M, up 4.5% from $128M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Birchview Capital's Q2 2023 filing shows 1 new, 8 increased, 3 reduced and 2 closed positions. Its largest new stake was Axogen: 40,000 shares worth $365K. The largest sale was Harrow, an estimated $660K.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2023 buy was Axogen: 40,000 shares worth $365K.
  • Birchview Capital added most to Prothena Corp in Q2 2023, an estimated $1.79M increase.
  • Birchview Capital's biggest Q2 2023 reduction was Harrow, cutting an estimated $660K.
  • Birchview Capital fully exited Elicio Therapeutics in Q2 2023, selling an estimated $32K.
  • Birchview Capital's ten largest holdings make up 73% of its $133M portfolio in Q2 2023.
  • Birchview Capital opened 1 new position and closed 2 in Q2 2023.
  • Birchview Capital's portfolio value rose 4.5% quarter-over-quarter to $133M.

Based on Birchview Capital's 13F filing for Q2 2023, filed 8 Aug 2023.